The company's financial performance shows a significant decline in revenue and increased cash burn, despite a reduced net loss. The Q&A section highlights uncertainties with AbbVie milestones and unclear management responses, adding to investor concerns. Additionally, the cash runway suggests potential liquidity issues. These factors, combined with competitive pressures and regulatory risks, likely lead to a negative stock price reaction.
